Form D · Biotechnology
Inivata Ltd
Cambridge, X0 · CIK 0001814307
Offering snapshot reported Jun 8, 2020 · SEC filing
- Reported sold
- $25M Offering amount: $60M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 22, 2020 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 8, 2020 | Initial | $25,000,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- Yes
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-368432
The investor in the initial closing invested $12,500,000 and will invest the remaining $12,500,000 at a second closing in August 2020.
Source: Form D, filed Jun 8, 2020. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Jeffrey Buchalter | Director |
| Ip2 Ipo Services Limited | Director |
| Clive Morris | Director, Executive |
| Timothy Shannon | Executive |
| Robert Tansley | Director |
| Douglas M. Van Ort | Director |
| Peter Wright Smith | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
The Glenn Berge Building Babraham
Cambridge, X0, CB22 3FH
Cambridge, X0, CB22 3FH